医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Yabao Pharmaceuticals and Primary Peptides Announce Exclusive China Partnership

2015年09月16日 AM01:00
このエントリーをはてなブックマークに追加


 

BEIJING & VANCOUVER, British Columbia

Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange 600351), a leading pharmaceutical company in China, today announced an exclusive license with privately held Primary Peptides, Inc., to develop and commercialise innovative products targeting PTEN nuclear translocation for the treatment of stroke.

Under the terms of the agreement, Yabao receives exclusive rights to develop and commercialise in China, Taiwan and Hong Kong while Primary Peptides retains rights in all other markets. Financial terms were not disclosed.

“Yabao is pleased to be collaborating with Primary Peptides, a world leader in development of new peptide therapeutics in the cardiovascular and neuroscience areas,” commented Dr. Peng Wang, President R&D, Yabao Pharmaceutical Co. “This opportunity for Yabao to expand on leading research to develop innovative products is further evidence of Yabao’s growing commitment to partner the best science to treat serious diseases in China.”

Dr. Max Cynader at Primary Peptides said, “We are pleased to combine our expertise in early innovative drug discovery with the significant resources that Yabao Pharmaceutical Co. can bring to developing groundbreaking new medicines. Brain protection following stroke represents a large unmet medical need, and this new peptide therapeutic has the potential to improve the lives of many stroke victims.”

About Yabao Pharmaceutical Co.

Yabao Pharmaceutical Co. (Shanghai Stock Exchange 600351) is a leading China pharmaceutical company with fully-integrated development, manufacturing, and commercialization in China. Yabao is recently pursuing strategic development of innovative pharmaceuticals in addition to Yabao’s well-established business in modern traditional Chinese medicines and chemical generics. In addition to strong clinical and regulatory capabilities, Yabao has strong capabilities in formulation and API production and meets good manufacturing practice (cGMP) requirements with two manufacturing sites approved by U.S. FDA and a European agency, respectively. For more information about Yabao Pharmaceutical Co., please visit www.yabao.com.cn

About Primary Peptides

Primary Peptides is a development stage biotech company that has developed a proprietary platform technology enabling it to identify, target, and disrupt specific protein-protein interactions leading to new peptide therapeutics for unmet medical needs. Our peptides can also replace SiRNA in many indications with improved pharmacokinetics and specificity. Primary Peptides has developed lead compounds in several neuroscience and cardiovascular indications.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150915005035/en/

CONTACT

Yabao Pharmaceutical Co.
Ms. Weina Liu, +86-10-5808-6285
liuweina@yabaoyaoye.com
or
Primary
Peptides
Dr. Max Cynader, 1-604-649-2274
cynader@brain.ubc.ca

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表